title: Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
abstract: Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely attributable to saturation of intestinal efflux abilities leading to higher absorption with higher doses. This study evaluated the membrane permeability of mirabegron and investigated the involvement of human intestinal transport proteins in the membrane permeation of mirabegron. Transcellular transport and cellular/vesicular uptake assays were performed using Caco-2 cells and/or human intestinal efflux (P-glycoprotein [P-gp], breast cancer resistance protein [BCRP], and multidrug resistance associated protein 2 [MRP2]) and influx (peptide transporter 1 [PEPT1], OATP1A2, and OATP2B1) transporter-expressing cells, vesicles, or Xenopus laevis oocytes. The absorptive permeability coefficients of mirabegron in Caco-2 cells (1.68-1.83 × 10(-6) cm/s) at the apical and basal pH of 6.5 and 7.4, respectively, were slightly higher than those of nadolol (0.97-1.41 × 10(-6) cm/s), a low permeability reference standard, but lower than those of metoprolol and propranolol (both ranged from 8.49 to 11.6 × 10(-6) cm/s), low/high permeability boundary reference standards. Increasing buffer pH at the apical side from 5.5 to 8.0 gradually increased the absorptive permeation of mirabegron from 0.226 to 1.66 × 10(-6) cm/s, but was still less than the value in the opposite direction (11.0-14.2 × 10(-6) cm/s). The time- and concentration-dependent transport of mirabegron was observed in P-gp-expressing cells and OATP1A2-expressing oocytes with apparent Km values of 294 and 8.59 μM, respectively. In contrast, no clear BCRP-, MRP2-, PEPT1-, or OATP2B1-mediated uptake of mirabegron was observed in their expressing vesicles or cells. These findings suggest that mirabegron has low-to-moderate membrane permeability and P-gp is likely to be involved in its efflux into the lumen in the intestinal absorption process. The results also suggest that mirabegron could possibly be transported by intestinal influx transporters as well as simple diffusion.
authors.affiliation: Drug Metabolism Research Laboratories, Astellas Pharma Inc., Osaka, Japan. shin.takusagawa@astellas.com
authors.forename: Shin
authors.initials: S
authors.lastname: Takusagawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ushigome
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nemoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Qun
authors.initials: Q
authors.lastname: Li
authors.forename: Virginie
authors.initials: V
authors.lastname: Kerbusch
authors.forename: Aiji
authors.initials: A
authors.lastname: Miyashita
authors.forename: Takafumi
authors.initials: T
authors.lastname: Iwatsubo
authors.forename: Takashi
authors.initials: T
authors.lastname: Usui
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D000083:Acetanilides / Q000493:pharmacokinetics*; D058667:Adrenergic beta-3 Receptor Agonists / Q000493:pharmacokinetics*; D000818:Animals; D001682:Biological Availability; D001693:Biological Transport, Active; D018938:Caco-2 Cells; D002463:Cell Membrane Permeability; D005260:Female; D057809:HEK293 Cells; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption / Q000502:physiology; D018374:LLC-PK1 Cells; D009363:Neoplasm Proteins / Q000378:metabolism; D009865:Oocytes / Q000378:metabolism; D027361:Organic Anion Transporters / Q000378:metabolism; D000074011:Peptide Transporter 1; D011994:Recombinant Proteins / Q000378:metabolism; D013552:Swine; D027981:Symporters / Q000378:metabolism; D013844:Thiazoles / Q000493:pharmacokinetics*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy; D014982:Xenopus laevis
chemical_list: C116614:ABCG2 protein, human; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D009363:Neoplasm Proteins; D027361:Organic Anion Transporters; D000074011:Peptide Transporter 1; D011994:Recombinant Proteins; C082186:SLC15A1 protein, human; C512988:SLCO1A2 protein, human; C450859:SLCO2B1 protein, human; D027981:Symporters; D013844:Thiazoles; C520025:mirabegron